Bengaluru, Karnataka, India: Aug 04, 2023
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced several key leadership appointments which will play an important role in transforming the organization and realizing the Company’s ambition of building a global biosimilars leader.
Rhonda Duffy has been appointed Chief Operating Officer (COO) and will lead Manufacturing, Quality and Supply Chain Management. She brings over 30-years of experience in the global pharmaceuticals industry.
Dr. Sandeep Athalye who has been with Biocon Biologics for over 6 years as its Chief Medical Officer has been elevated to Chief Development Officer to head CMC, Clinical Development and Medical and Regulatory Affairs.
David Gibson joins the Company from GlaxoSmithKline (GSK) to lead all licensing, strategic partnering and business development activities as its Global Head – Business Development
Stephanie Wasco joins as Head of Communications – Advanced Markets to lead Corporate and Marketing Communications and Product Branding in Advanced Markets such as the US and Europe.
In addition to the above key leadership appointments, the Company has on-boarded global leadership talent across several functions including Manufacturing Science and Technology (MSAT), Clinical Development, Finance, HR, Legal and Compliance.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics said: “These new additions to the leadership team bring rich, global experience which will help prepare the organization for the future and ensure a seamless integration of the recently acquired global biosimilars business from Viatris. In doing so, it will allow us to enhance performance, reliability and sustainability while delivering on our commitment of bringing high-quality affordable biosimilars to millions of patients across the globe.”
strong>About Biocon Biologics Limited:
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world- class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.
BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., EU, Australia, Canada, Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people and the planet to achieve key UN Sustainable Development Goals (SDGs).
Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.